Andrew Baum
Stock Analyst at Citigroup
(2.88)
# 1,542
Out of 5,140 analysts
67
Total ratings
76.74%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $53 → $60 | $60.66 | -1.09% | 15 | Jan 27, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $26.65 | -2.44% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $122.26 | -5.94% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $45.12 | -11.35% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $224.81 | -4.36% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $1,009.52 | -11.34% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $4.14 | +141.55% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $59.52 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Jan 27, 2026
Maintains: Neutral
Price Target: $53 → $60
Current: $60.66
Upside: -1.09%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $26.65
Upside: -2.44%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $122.26
Upside: -5.94%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $45.12
Upside: -11.35%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $224.81
Upside: -4.36%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $1,009.52
Upside: -11.34%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $4.14
Upside: +141.55%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $59.52
Upside: -